Spinal cord stimulation means the spinal cord is being repaired
What Patients SayI saw a news report about paralysed patients walking again after spinal cord stimulation. Does this mean the spinal cord can repair itself if you stimulate it? And does this work for my type of injury?
Where Did This Come From?
The headlines have been extraordinary. "Paralysed man walks again." "Patients with SCI regain hand function." "Stimulation reverses paralysis." These are real results from real studies — and they are also real misunderstandings waiting to happen.
Spinal cord stimulation (SCS) for chronic pain has existed for decades. You may have seen it mentioned earlier in this booklet as a treatment for neuropathic pain. That application — where electrodes modulate pain signals in the dorsal columns — is well-established, FDA-approved, and quite different from what the recent headlines are describing.
The recent wave of results concerns a different application: using targeted electrical stimulation to augment residual motor and sensory function in people with incomplete spinal cord injuries. The most widely reported study in this context is the ARC-EX trial, published in Nature Medicine in 2024 — a multicenter trial of transcutaneous (non-invasive, applied to the skin over the cervical cord) spinal cord stimulation combined with structured rehabilitation in 60 patients with chronic cervical SCI. 72% of participants demonstrated meaningful improvements in arm and hand strength and function compared to an equivalent period of rehabilitation alone. No serious adverse events were reported.
This is genuinely important and exciting evidence.
Here is what it does not mean. The stimulation does not repair the spinal cord. It does not regenerate severed axons. It does not rebuild the glial scar or reconnect severed circuits. What it appears to do — and the mechanisms are still being characterised — is amplify the activity of surviving neural circuits: spared axons that still exist but are not functioning at full capacity because they are receiving insufficient excitatory drive. Stimulation increases the excitability of these pathways, making residual connections more responsive during active rehabilitation. Combined with intensive, task-specific training, this allows the nervous system to reorganise (neuroplasticity) around surviving connections.
This is why patient selection is so critical. The ARC-EX results were in patients with cervical, predominantly incomplete injuries — meaning patients who had preserved some cord continuity. Patients with clinically complete injuries (no preserved pathways) have a fundamentally different biological situation. The results from incomplete SCI trials cannot be directly extrapolated to complete SCI. This distinction is often lost in headlines.
A separate consideration: spinal cord stimulation for chronic back pain — the most common SCS application — does not improve neurological function and should not be conflated with the SCI rehabilitation results above. These are different technologies applied to different populations for different purposes.
The Verdict
Spinal cord stimulation, in appropriate patients with incomplete SCI, combined with intensive rehabilitation, can meaningfully improve function. It works through augmenting surviving circuits, not repairing the injured cord. The results depend heavily on injury completeness, timing, and rehabilitation intensity.
What To Do Instead
- Ask your SCI specialist specifically whether your injury is complete (ASIA A) or incomplete (ASIA B, C, or D) — this is the most important predictor of whether stimulation-based rehabilitation applies to you
- Understand that ARC-EX and similar systems work in combination with intensive rehabilitation — not as standalone passive treatments
- If you have chronic back pain and SCS is being discussed, understand this is a different conversation from the SCI recovery headlines — ask your specialist which application is relevant for you
- Seek evaluation at a comprehensive SCI rehabilitation centre for any decision about stimulation-based therapies
Yellow Flags — Worth Monitoring
- Any non-specialist offering SCS for SCI rehabilitation outside of a structured trial or specialist SCI rehabilitation programme
- Claims that SCS works for complete (ASIA A) injuries based on results from predominantly incomplete injury trials
Red Flags — Seek Independent Advice
- Implanted epidural SCS offered for neurological SCI recovery (as opposed to chronic pain) outside of a registered clinical trial — implanted devices for SCI neuromodulation remain investigational and require specialist neurosurgical assessment
- Any provider conflating SCS for chronic pain with SCS for SCI neurological recovery — these are distinct indications with distinct evidence bases
- Calvert JS et al., "Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia," Nature Medicine, 2024;30(5):1276–1283. (ARC-EX trial: 72% of 60 participants with chronic cervical SCI met primary effectiveness endpoint; no serious adverse events.)
- Megia Garcia A et al., "ARC EX Therapy for chronic cervical SCI," Neurology, 2024. (Home-based and clinic-based ARC-EX both safe and effective; 72% primary endpoint met.)
- BEYOND THE MYTH — Part 10 Supplementary Topics
- These topics are raised frequently enough to deserve honest answers, but are better covered as short explanations than as full chapters.
- "If it worked in rats, it will work in humans"
- Animal models have driven spinal cord injury and disc degeneration research for decades, and some of the most promising early-stage results — complete neurological recovery in rodents after various interventions — created enormous public excitement. The translation gap is real and persistent.
- Why animal results frequently do not replicate in humans:
- Rodent spinal cords are anatomically and functionally different from human cords
- The timing of injury to intervention in animal studies is often acute; most human patients present sub-acutely or chronically, when the injury environment is completely different
- Animal study sample sizes are typically small, and publication bias means negative results are underrepresented
- Outcome measures in animals (grid walking, swimming, beam walking) do not map directly to human functional outcomes
- A 2019 analysis from Ohio State University found widespread bias in SCI animal studies — including failure to report excluded animals, absence of allocation concealment, and lack of blinded outcome assessment — leading to systematic overestimation of treatment efficacy
- This does not mean animal studies are worthless. They are essential for generating hypotheses and understanding mechanisms. But they are the first step of a long journey, not evidence that a treatment works in humans.
- "A clinical trial listing means the treatment is proven"
- ClinicalTrials.gov is a database that registers clinical research — not a registry of approved or proven treatments. The FDA specifically states that listing on ClinicalTrials.gov does not mean a product is legally marketed, FDA-approved, or proven effective.
- The difference between trial phases matters enormously:
- Phase 1: Safety and dosing — a small number of patients, primary goal is to establish whether the treatment causes serious harm
- Phase 2: Efficacy signal — is there evidence it might work? Still too early to recommend broadly
- Phase 3: Definitive efficacy — large, randomised, controlled trial required before approval
- FDA approval: The end point of this process — not the beginning
- When a clinic tells you a treatment is "in clinical trials" or "being studied at major centres," that is a description of where the science is — it is not a basis for paying for it outside of those trials.
- "FDA registered means FDA approved"
- FDA registration describes a facility that has met administrative requirements to operate. FDA approval describes a product that has been reviewed and found safe and effective for a specific indication through a full regulatory process.
- These are completely different things. A clinic can be FDA-registered and offer nothing that is FDA-approved. A product can be "FDA listed" — entered into a database — without having been reviewed or approved.
- When evaluating any regenerative medicine claim, ask specifically: "Is this product FDA-approved for my indication?" Not "registered," not "listed," not "recognised," not "compliant" — approved.
- "My own cells cannot harm me — autologous means safe"
- Autologous means derived from your own body. It does not mean safe. Several important risks remain:
- Processing contamination: Between harvest and re-injection, autologous cells are processed, concentrated, and sometimes cultured. Each step introduces contamination risk.
- Wrong tissue behaviour: Adipose-derived cells injected into the disc or spinal fluid may not behave as intended — they enter a completely different microenvironment from where they originated.
- Inflammatory reaction: Reintroducing processed cells into a new anatomical location can trigger local inflammatory responses, particularly in the avascular disc environment.
- Intrathecal injection risks: Injecting any substance into the spinal fluid — including your own cells — carries risks of headache, infection, and potentially serious neurological events if contamination or inflammatory responses occur at this anatomical level.
- The FDA specifically notes that autologous products are not exempt from regulation simply because they originate from the patient's own body — if the processing steps are extensive enough to constitute manufacture of a biological product, FDA oversight applies.
- "Walking is the only recovery that matters after SCI"
- Research consistently shows that people with SCI rank priorities differently from what outside observers assume. When patients with spinal cord injury are asked directly what recovery matters most to them:
- Hand and arm function is the top priority for tetraplegic patients — more so than walking
- Bladder and bowel function is consistently ranked as a top-three priority across injury levels
- Sexual function, reduction of chronic pain, spasticity control, and trunk stability matter enormously for independence and quality of life
- Walking, while deeply symbolic, is ranked lower than clinicians and families often assume
- This matters for two reasons. First, it changes how we should evaluate research outcomes — a trial showing improved hand grip in tetraplegics may be more clinically meaningful than one showing limited locomotor recovery. Second, it protects patients from fixating on an outcome that may not be achievable while overlooking gains that would substantially change their daily lives.
- The most sophisticated, patient-centred rehabilitation programmes are organised around what the patient actually values — not what looks best in a fundraising video.
- Complete vs. Incomplete Spinal Cord Injury — the distinction that changes everything
- The American Spinal Injury Association (ASIA) Impairment Scale grades neurological status from A to E:
- ASIA A (Complete): No sensory or motor function preserved below the level of injury. The cord has essentially no preserved pathways at the injury level.
- ASIA B: Sensory but not motor function preserved below the neurological level.
- ASIA C: Motor function preserved below the neurological level; more than half of key muscles grade less than 3/5.
- ASIA D: Motor function preserved; at least half of key muscles grade 3/5 or above.
- ASIA E: Normal.
- The distinction between A and B/C/D is profoundly important for prognosis, for eligibility for certain interventions, and for understanding what recovery is possible. Most of the dramatic recovery stories in the media — including many involving stimulation and stem cells — involve incomplete injuries (B, C, or D). Some degree of spontaneous neurological recovery can also occur in incomplete injuries in the first 6–12 months even without specific intervention.
- When evaluating any claim about SCI treatment, always ask: what was the ASIA grade of the patients included?
- End of Part 10.
- PART 10 — Reference Summary